Nisa Investment Advisors
TELO icon

Nisa Investment Advisors’s Telomir Pharmaceuticals TELO Stock Holding History

Nisa Investment Advisors’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-96
Closed -$120 – 3105
2025
Q2 		$120 Sell
96
-87
-48% -$201 ﹤0.01% 3025
2025
Q1 		$591 Buy
183
+51
+39% +$223 ﹤0.01% 2763
2024
Q4 		$544 Buy
+132
New +$622 ﹤0.01% 2819

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nisa Investment Advisors's TELO Position: Q3 2025 in Review

Nisa Investment Advisors sold out of Telomir Pharmaceuticals (TELO) in Q3 2025, closing a stake of 96 shares — an estimated $120 sold.

Nisa Investment Advisors first reported a position in TELO in Q4 2024 and held it in 3 quarters. The position peaked at $591 in Q1 2025. 32 funds tracked by Wall St. Rank hold TELO as of Q3 2025.

  • Nisa Investment Advisors reported no remaining Telomir Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Nisa Investment Advisors sold 96 Telomir Pharmaceuticals shares in Q3 2025, an estimated $120.
  • Nisa Investment Advisors first reported a position in Telomir Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Nisa Investment Advisors's Telomir Pharmaceuticals position peaked at $591 in Q1 2025.
  • 32 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q3 2025.

Based on Nisa Investment Advisors's 13F filing for Q3 2025, filed 23 Oct 2025.